Nanomedicine delivers promising treatments for rheumatoid arthritis

Nanomedicine

Volumn 10, Issue 13, 2015, Pages 2063-2074

  Prasad, Leena Kumari ^a   O'Mary, Hannah ^a   Cui, Zhengrong ^a,b  

^a UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^b INNER MONGOLIA MEDICAL UNIVERSITY   (China)

Author keywords

chronic inflammation; enhanced permeability and retention; liposomes; nanomedicine; nanoparticles; rheumatoid arthritis

Indexed keywords

ANGIOGENESIS INHIBITOR; BIOLOGICAL PRODUCT; CELL RECEPTOR; CORTICOSTEROID; DNA TOPOISOMERASE INHIBITOR; FOLIC ACID ANTAGONIST; GAMMA SECRETASE INHIBITOR; GOLD DERIVATIVE; IMMUNOMODULATING AGENT; NANOCARRIER; NANOPARTICLE; NONSTEROID ANTIINFLAMMATORY AGENT;

CHRONIC INFLAMMATION; CONJUGATION; DRUG DELIVERY SYSTEM; DRUG PENETRATION; GENE THERAPY; HUMAN; LIGAND BINDING; MACROPHAGE; NANOENCAPSULATION; NANOMEDICINE; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; RHEUMATOID ARTHRITIS; ANIMAL; ARTHRITIS, RHEUMATOID; METABOLISM; PATHOLOGY; PERMEABILITY; PROCEDURES;

ANIMALS; ARTHRITIS, RHEUMATOID; DRUG DELIVERY SYSTEMS; HUMANS; NANOMEDICINE; PERMEABILITY;

EID: 84937501117     PISSN: 17435889     EISSN: 17486963     Source Type: Journal    
DOI: 10.2217/nnm.15.45     Document Type: Review

References (100)

1. Bian Z, Guo Y, Ha B, Zen K, Liu Y. Regulation of the inflammatory response: enhancing neutrophil infiltration under chronic inflammatory conditions. J. Immunol. 188(2), 844-853 (2012).
2. Fadok VA, Bratton DL, Konowal A, Freed PW, Westcott JY, Henson PM. Macrophages that have ingested apoptotic cells in vitro inhibit proinflammatory cytokine production through autocrine/paracrine mechanisms involving TGFbeta, PGE2, and PAF. J. Clin. Invest. 101(4), 890-898 (1998).
3. Abe R, Donnelly SC, Peng T, Bucala R, Metz CN. Peripheral blood fibrocytes: differentiation pathway and migration to wound sites. J. Immunol. 166(12), 7556-7562 (2001).
4. Kumar V, Abbas AK, Fausto N, Mitchell RN. Robbins Basic Pathology (8th Edition). Saunders/Elsevier Health Sciences, PA, USA, 31-58 (2007).
5. Fichtner-Feigl S, Strober W, Geissler EK, Schlitt HJ. Cytokines mediating the induction of chronic colitis and colitis-associated fibrosis. Mucosal Immunol. 1, S24-S27 (2008).
6. Kennedy A, Deleo F. Neutrophil apoptosis and the resolution of infection. Immunol. Res. 43(1-3), 25-61 (2009).
7. Reddy NM, Kleeberger SR, Kensler TW, Yamamoto M, Hassoun PM, Reddy SP. Disruption of Nrf2 Impairs the resolution of hyperoxia-induced acute lung injury and inflammation in mice. J. Immunol. 182(11), 7264-7271 (2009).
8. Mcinnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N. Engl. J. Med. 365(23), 2205-2219 (2011).
9. Sartor RB. Mechanisms of disease: pathogenesis of Crohn's disease and ulcerative colitis. Nat. Clin. Pract. Gastroenterol. Hepatol. 3, 390-407 (2006).
10. Tuder RM, Petrache I. Pathogenesis of chronic obstructive pulmonary disease. J. Clin. Invest. 122(8), 2749-2755 (2012).
11. Scott DL, Wolfe F, Huizinga TWJ. Rheumatoid arthritis. Lancet 376(9746), 1094-1108 (2010).
12. Cooper NJ. Economic burden of rheumatoid arthritis: a systematic review. Rheumatology (Oxford) 39(1), 28-33 (2000).
13. Park KT, Bass D. Inflammatory bowel disease-attributable costs and cost-effective strategies in the United States: a review. Inflammat. Bowel Dis. 17(7), 1603-1609 (2011).
14. Lajas C, Abasolo L, Bellajdel B et al. Costs and predictors of costs in rheumatoid arthritis: a prevalence-based study. Arthritis Care Res. 49(1), 64-70 (2003).
15. Prenzler A, Bokemeyer B, Schulenburg JM, Mittendorf T. Health care costs and their predictors of inflammatory bowel diseases in Germany. Eur. J. Health Econ. 12(3), 273-283 (2011).
16. Jacobs P, Bissonnette R, Guenther LC. Socioeconomic burden of immune-mediated inflammatory diseases-focusing on work productivity and disability. J. Rheumatol. 88, 55-61 (2011).
17. Birnbaum H, Pike C, Kaufman R, Maynchenko M, Kidolezi Y, Cifaldi M. Societal cost of rheumatoid arthritis patients in the US. Curr. Med. Res. Opin. 26(1), 77-90 (2010).
18. Teunou E, Poncelet D. Batch and continuous fluid bed coating-review and state of the art. J. Food Eng. 53(4), 325-340 (2002).
19. Smolen JS, Redlich K. The Autoimmune Diseases (5th Edition). Rose NR, Mackay IR (Eds). Elsevier/Academic Press, Amsterdam, The Netherlands, 511-523 (2006).
20. ͈enolt L, Vencovský J, Pavelka K, Ospelt C, Gay S. Prospective new biological therapies for rheumatoid arthritis. Autoimmun. Rev. 9(2), 102-107 (2009).
21. Bayry J, Kaveri SV, Kazatchkine MD, Lacroix-Desmazes S. Monoclonal antibody and intravenous immunoglobulin therapy for rheumatic diseases: rationale and mechanisms of action. Nat. Clin. Pract. Rheumatol. 3(5), 262-272 (2007).
22. Santamaria P. Cytokines and Chemokines in Autoimmune Disease: An Overview. Landes Bioscience, TX, USA (2003).
23. Morel J, Berenbaum F. Signal transduction pathways: new targets for treating rheumatoid arthritis. Joint Bone Spine 71(6), 503-510 (2004).
24. Cohen SB, Cheng T-T, Chindalore V et al. Evaluation of the efficacy and safety of pamapimod, a p38 MAP kinase inhibitor, in a double-blind, methotrexate-controlled study of patients with active rheumatoid arthritis. Arthritis Rheumat. 60(2), 335-344 (2009).
25. Weinblatt ME, Kavanaugh A, Burgos-Vargas R et al. Treatment of rheumatoid arthritis with a Syk kinase inhibitor: a twelve-week, randomized, placebo-controlled trial. Arthritis Rheumat. 58(11), 3309-3318 (2008).
26. Duncan R, Gaspar R. Nanomedicine(s) under the microscope. Mol. Pharm. 8(6), 2101-2141 (2011).
27. Nitsche JM, Chang H-C, Weber PA, Nicholson BJ. A transient diffusion model yields unitary gap junctional permeabilities from images of cell-to-cell fluorescent dye transfer between xenopus oocytes. Biophys. J. 86(4), 2058-2077 (2004).
28. Weber PA, Chang H-C, Spaeth KE, Nitsche JM, Nicholson BJ. The permeability of gap junction channels to probes of different size is dependent on connexin composition and permeant-pore affinities. Biophys. J. 87(2), 958-973 (2004).
29. Dhein S. Gap junction channels in the cardiovascular system: pharmacological and physiological modulation. Trends Pharmacol. Sci. 19(6), 229-241 (1998).
30. Revel JP, Karnovsky MJ. Hexagonal array of subunits in intercellular junctions of the mouse heart and liver. J. Cell Biol. 33(3), C7-C12 (1967).
31. Maeda H. The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. Adv. Enzyme Regul. 41(1), 189-207 (2001).
32. Yuan F, Dellian M, Fukumura D et al. Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size. Cancer Res. 55(17), 3752-3756 (1995).
33. Castro E, Kumar A. Nanomedicine in Drug Delivery. Kumar A, Mansour HM, Friedman A, Blough ER (Eds). CRC Press/Taylor & Francis Group, FL, USA, 1-22 (2013).
34. Gupta RB. Nanoparticle Technology for Drug Delivery. Gupta RB, Kompella UB (Eds). Taylor & Francis, NY, USA, 1-20 (2006).
35. Veronese F, Mero A, Pasut G. Protein PEGylation, basic science and biological applications. In: PEGylated Protein Drugs: Basic Science and Clinical Applications. Veronese F (Ed.). Birkhäuser Verlag, Basel, Switzerland, 11-31 (2009).
36. Gabizon AA. PEGylated liposomal doxorubicin: metamorphosis of an old drug into a new form of chemotherapy. Cancer Invest. 19(4), 424-436 (2001).
37. Maeda H. Tumor-selective delivery of macromolecular drugs via the EPR effect: background and future prospects. Bioconjug. Chem. 21(5), 797-802 (2010).
38. Maeda H. The link between infection and cancer: tumor vasculature, free radicals, and drug delivery to tumors via the EPR effect. Cancer Sci. 104(7), 779-789 (2013).
39. Ochoa CD, Stevens T. Studies on the cell biology of interendothelial cell gaps. Am. J. Physiol. 302(3), L275-L286 (2012).
40. Szekanecz Z, Koch A. Chemokines and cytokines in inflammatory angiogenesis. In: Angiogenesis in Inflammation: Mechanisms and Clinical Correlates. Seed M, Walsh D (Eds). Birkhäuser Verlag, Basel, Switzerland, 83-98 (2008).
41. Sans M, Panés J, Ardite E et al. VCAM-1 and ICAM-1 mediate leukocyte-endothelial cell adhesion in rat experimental colitis. Gastroenterology 116(4), 874-883 (1999).
42. Koo O, Rubinstein I, Önyüksel H. Actively targeted lowdose camptothecin as a safe, long-acting, disease-modifying nanomedicine for rheumatoid arthritis. Pharm. Res. 28(4), 776-787 (2011).
43. Martinez-Lostao L, Garcia-Alvarez F, Basanez G et al. Liposome-bound APO2L/TRAIL is an effective treatment in a rabbit model of rheumatoid arthritis. Arthritis Rheumat. 62(8), 2272-2282 (2010).
44. ClinicalTrials.gov. www.clinicaltrials.gov
45. Chiong HS, Yong YK, Ahmad Z et al. Cytoprotective and enhanced anti-inflammatory activities of liposomal piroxicam formulation in lipopolysaccharide-stimulated RAW 264.7 macrophages. Int. J. Nanomedicine 8, 1245-1255 (2013).
46. Turk CTS, Oz UC, Serim TM, Hascicek C. Formulation and optimization of nonionic surfactants emulsified nimesulide-loaded PLGA-based nanoparticles by design of experiments. AAPS PharmSciTech 15(1), 161-176 (2014).
47. James LRA, Xu Z-Q, Sluyter R et al. An investigation into the interactions of gold nanoparticles and anti-arthritic drugs with macrophages, and their reactivity towards thioredoxin reductase. J. Inorg. Biochem. 142(0), 28-38 (2015).
48. Hofkens W, Grevers LC, Walgreen B et al. Intravenously delivered glucocorticoid liposomes inhibit osteoclast activity and bone erosion in murine antigen-induced arthritis. J. Control. Release 152(3), 363-369 (2011).
49. Hofkens W, Storm G, Van Den Berg WB, Van Lent PL. Liposomal targeting of glucocorticoids to the inflamed synovium inhibits cartilage matrix destruction during murine antigen-induced arthritis. Int. J. Pharm. 416(2), 486-492 (2011).
50. Hofkens W, Van Den Hoven JM, Pesman GJ et al. Safety of glucocorticoids can be improved by lower yet still effective dosages of liposomal steroid formulations in murine antigen-induced arthritis: comparison of prednisolone with budesonide. Int. J. Pharm. 416(2), 493-498 (2011).
51. Hofkens W, Schelbergen R, Storm G, Van Den Berg WB, Van Lent PL. Liposomal targeting of prednisolone phosphate to synovial lining macrophages during experimental arthritis inhibits M1 activation but does not favor M2 differentiation. PLoS ONE 8(2), e54016 (2013).
52. Metselaar JM, Van Den Berg WB, Holthuysen AE, Wauben MH, Storm G, Van Lent PL. Liposomal targeting of glucocorticoids to synovial lining cells strongly increases therapeutic benefit in collagen type II arthritis. Ann. Rheumat. Dis. 63(4), 348-353 (2004).
53. Ulmansky R, Turjeman K, Baru M et al. Glucocorticoids in nano-liposomes administered intravenously and subcutaneously to adjuvant arthritis rats are superior to the free drugs in suppressing arthritis and inflammatory cytokines. J. Control. Release 160(2), 299-305 (2012).
54. Avnir Y, Ulmansky R, Wasserman V et al. Amphipathic weak acid glucocorticoid prodrugs remote-loaded into sterically stabilized nanoliposomes evaluated in arthritic rats and in a Beagle dog: a novel approach to treating autoimmune arthritis. Arthritis Rheumat. 58(1), 119-129 (2008).
55. Hwang J, Rodgers K, Oliver JC, Schluep T. Alphamethylprednisolone conjugated cyclodextrin polymer-based nanoparticles for rheumatoid arthritis therapy. Int. J. Nanomedicine 3(3), 359-371 (2008).
56. Ishihara T, Kubota T, Choi T, Higaki M. Treatment of experimental arthritis with stealth-type polymeric nanoparticles encapsulating betamethasone phosphate. J. Pharm. Exp. Ther. 329(2), 412-417 (2009).
57. Anderson R, Franch A, Castell M et al. Liposomal encapsulation enhances and prolongs the anti-inflammatory effects of water-soluble dexamethasone phosphate in experimental adjuvant arthritis. Arthritis Res. Ther. 12(4), R147 (2010).
58. Rauchhaus U, Schwaiger FW, Panzner S. Separating therapeutic efficacy from glucocorticoid side-effects in rodent arthritis using novel, liposomal delivery of dexamethasone phosphate: long-term suppression of arthritis facilitates interval treatment. Arthritis Res. Ther. 11(6), R190 (2009).
59. Koning GA, Schiffelers RM, Wauben MH et al. Targeting of angiogenic endothelial cells at sites of inflammation by dexamethasone phosphate-containing RGD peptide liposomes inhibits experimental arthritis. Arthritis Rheumat. 54(4), 1198-1208 (2006).
60. Quan L, Zhang Y, Crielaard BJ et al. Nanomedicines for inflammatory arthritis: head-to-head comparison of glucocorticoid-containing polymers, micelles, and liposomes. ACS Nano 8(1), 458-466 (2013).
61. Bartneck M, Peters FM, Warzecha KT et al. Liposomal encapsulation of dexamethasone modulates cytotoxicity, inflammatory cytokine response, and migratory properties of primary human macrophages. Nanomedicine 10(6), 1209-1220 (2014).
62. Thomas TP, Goonewardena SN, Majoros IJ et al. Folatetargeted nanoparticles show efficacy in the treatment of inflammatory arthritis. Arthritis Rheumat. 63(9), 2671-2680 (2011).
63. Mello SB, Tavares ER, Bulgarelli A, Bonfa E, Maranhao RC. Intra-articular methotrexate associated to lipid nanoemulsions: anti-inflammatory effect upon antigeninduced arthritis. Int. J. Nanomedicine 8, 443-449 (2013).
64. Moura CC, Segundo MA, Neves JD, Reis S, Sarmento B. Co-association of methotrexate and SPIONs into anti-CD64 antibody-conjugated PLGA nanoparticles for theranostic application. Int. J. Nanomedicine 9, 4911-4922 (2014).
65. Abolmaali SS, Tamaddon A, Yousefi G, Javidnia K, Dinarvand R. Sequential optimization of methotrexate encapsulation in micellar nano-networks of polyethyleneimine ionomer containing redox-sensitive crosslinks. Int. J. Nanomedicine 9, 2833-2848 (2014).
66. Wahba SMR, Darwish AS, Shehata IH, Abd Elhalem SS. Sugarcane bagasse lignin, and silica gel and magneto-silica as drug vehicles for development of innocuous methotrexate drug against rheumatoid arthritis disease in albino rats. Mat. Sci. Eng. C 48, 599-610 (2015).
67. Wilson DR, Zhang N, Silvers AL, Forstner MB, Bader RA. Synthesis and evaluation of cyclosporine A-loaded polysialic acid-polycaprolactone micelles for rheumatoid arthritis. Eur. J. Pharm. Sci. 51, 146-156 (2014).
68. Kim YJ, Chae SY, Jin CH et al. Ionic complex systems based on hyaluronic acid and PEGylated TNF-related apoptosisinducing ligand for treatment of rheumatoid arthritis. Biomaterials 31(34), 9057-9064 (2010).
69. Chuan YP, Zeng BY, O'Sullivan B, Thomas R, Middelberg AP. Co-delivery of antigen and a lipophilic antiinflammatory drug to cells via a tailorable nanocarrier emulsion. J. Colloid Interface Sci. 368(1), 616-624 (2012).
70. Zhou HF, Yan H, Senpan A et al. Suppression of inflammation in a mouse model of rheumatoid arthritis using targeted lipase-labile fumagillin prodrug nanoparticles. Biomaterials 33(33), 8632-8640 (2012).
71. Heo R, Park J-S, Jang HJ et al. Hyaluronan nanoparticles bearing ?-secretase inhibitor: in vivo therapeutic effects on rheumatoid arthritis. J. Control. Release 192, 295-300 (2014).
72. Mease PJ, Wei N, Fudman EJ et al. Safety, tolerability, and clinical outcomes after intraarticular injection of a recombinant adeno-associated vector containing a tumor necrosis factor antagonist gene: results of a Phase 1/2 study. J. Rheumatol. 37(4), 692-703 (2010).
73. Foged C, Nielsen HM, Frokjaer S. Liposomes for phospholipase A2 triggered siRNA release: preparation and in vitro test. Int. J. Pharm. 331(2), 160-166 (2007).
74. Howard KA, Paludan SR, Behlke MA, Besenbacher F, Deleuran B, Kjems J. Chitosan/siRNA nanoparticlemediated TNF-alpha knockdown in peritoneal macrophages for anti-inflammatory treatment in a murine arthritis model. Mol. Ther. 17(1), 162-168 (2009).
75. Komano Y, Yagi N, Onoue I, Kaneko K, Miyasaka N, Nanki T. Arthritic joint-targeting small interfering RNAencapsulated liposome: implication for treatment strategy for rheumatoid arthritis. J. Pharm. Exp. Ther. 340(1), 109-113 (2012).
76. Khoury M, Louis-Plence P, Escriou V et al. Efficient new cationic liposome formulation for systemic delivery of small interfering RNA silencing tumor necrosis factor alpha in experimental arthritis. Arthritis Rheumat. 54(6), 1867-1877 (2006).
77. Te Boekhorst BCM, Jensen LB, Colombo S et al. MRIassessed therapeutic effects of locally administered PLGA nanoparticles loaded with anti-inflammatory siRNA in a murine arthritis model. J. Control. Release 161(3), 772-780 (2012).
78. Scheinman RI, Trivedi R, Vermillion S, Kompella UB. Functionalized STAT1 siRNA nanoparticles regress rheumatoid arthritis in a mouse model. Nanomedicine 6(10), 1669-1682 (2011).
79. Zhang T, Bai X, Mao X. Systemic delivery of small interfering RNA targeting the interleukin-2/15 receptor ? chain prevents disease progression in experimental arthritis. PLoS ONE 8(11), e78619 (2013).
80. Fernandes JC, Wang H, Jreyssaty C et al. Bone-protective effects of nonviral gene therapy with folate-chitosan DNA nanoparticle containing interleukin-1 receptor antagonist gene in rats with adjuvant-induced arthritis. Mol. Ther. 16(7), 1243-1251 (2008).
81. Jung Y-S, Park W, Na K. Temperature-modulated noncovalent interaction controllable complex for the longterm delivery of etanercept to treat rheumatoid arthritis. J. Control. Release 171(2), 143-151 (2013).
82. Sethi V, Rubinstein I, Kuzmis A, Kastrissios H, Artwohl J, Onyuksel H. Novel, Biocompatible, and disease modifying VIP nanomedicine for rheumatoid arthritis. Mol. Pharm. 10(2), 728-738 (2012).
83. Nakashima-Matsushita N, Homma T, Yu S et al. Selective expression of folate receptor ? and its possible role in methotrexate transport in synovial macrophages from patients with rheumatoid arthritis. Arthritis Rheumat. 42(8), 1609-1616 (1999).
84. Yusuf-Makagiansar H, Anderson ME, Yakovleva TV, Murray JS, Siahaan TJ. Inhibition of LFA-1/ICAM-1 and VLA-4/ VCAM-1 as a therapeutic approach to inflammation and autoimmune diseases. Medicinal Res. Rev. 22(2), 146-167 (2002).
85. Huang M-T, Mason JC, Birdsey GM et al. Endothelial intercellular adhesion molecule (ICAM)-2 regulates angiogenesis. Blood 106(5), 1636-1643 (2005).
86. Onat D, Brillon D, Colombo P, Schmidt A. Human vascular endothelial cells: a model system for studying vascular inflammation in diabetes and atherosclerosis. Curr. Diab. Rep. 11(3), 193-202 (2011).
87. Delgado M, Abad C, Martinez C et al. Vasoactive intestinal peptide in the immune system: potential therapeutic role in inflammatory and autoimmune diseases. J. Mol. Med. 80(1), 16-24 (2002).
88. Gaddy D, Robbins P. Current status of gene therapy for rheumatoid arthritis. Curr. Rheumatol. Rep. 10(5), 398-404 (2008).
89. Dizaj SM, Jafari S, Khosroushahi AY. A sight on the current nanoparticle-based gene delivery vectors. Nanoscale Res. Lett. 9(1), 252-252 (2014).
90. Liu C, Zhang N. Nanoparticles in gene therapy: principles, prospects, and challenges. In: Progress in Molecular Biology and Translational Science. Antonio V (Ed.). Academic Press, CA, USA, 509-562 (2011).
91. Danhier F, Ansorena E, Silva JM, Coco R, Le Breton A, Préat V. PLGA-based nanoparticles: an overview of biomedical applications. J. Control. Release 161(2), 505-522 (2012).
92. Yagi N, Manabe I, Tottori T et al. A Nanoparticle system specifically designed to deliver short interfering RNA inhibits tumor growth in vivo. Cancer Res. 69(16), 6531-6538 (2009).
93. Gura T. How TRAIL kills cancer cells, but not normal cells. Science 277(5327), 768 (1997).
94. Siddik ZH. apoptosis in cancer: mechanisms, deregulation, and therapeutic targeting. In: Cancer Drug Design and Discovery (2nd Edition). Neidle S (Ed.). Academic Press, CA, USA, 357-390 (2014).
95. Van Roosmalen IaM, Quax WJ, Kruyt FaE. Two deathinducing human TRAIL receptors to target in cancer: similar or distinct regulation and function? Biochem. Pharmacol. 91(4), 447-456 (2014).
96. Mellier G, Huang S, Shenoy K, Pervaiz S. TRAILing death in cancer. Mol. Aspects Med. 31(1), 93-112 (2010).
97. Duiker EW, Mom CH, De Jong S et al. The clinical trail of TRAIL. Eur. J. Cancer 42(14), 2233-2240 (2006).
98. Falschlehner C, Schaefer U, Walczak H. Following TRAIL's path in the immune system. Immunology 127(2), 145-154 (2009).
99. Tarrus M, Sloot A, Temming K et al. RGD-avidin-biotin pretargeting to ?v?3 integrin enhances the proapoptotic activity of TNF? related apoptosis inducing ligand (TRAIL). Apoptosis 13(2), 225-235 (2008).
100. Tinkle S, Mcneil SE, Mühlebach S et al. Nanomedicines: addressing the scientific and regulatory gap. Ann. NY Acad. Sci. 1313(1), 35-56 (2014).